Drug discovery is one of the keystone themes we cover on Nanalyze, and we’re not just talking about finding new cannabis dispensaries in the smoking Pacific Northwest. Creating novel medicines from scratch to treat disease isn’t cheap. A study published this year calculated it costs an average of $1.3 billion to develop a new drug […]
In a past article, we provided a basic overview of the FDA Drug Approval process and noted that Phase 1 of the approval process is focused on making sure the drug compound is safely metabolized in the human body. Prior to this phase, animal tests are conducted to try and predict whether the compound will […]
Several months ago, we published an article titled “Organs-on-Chips: An Alternative to 3D Bioprinting?” in which we speculated that 3D Bioprinting small samples of organ tissues to use for drug testing could be displaced by organs-on-chips. Organovo (NYSEMKT:ONVO), the only publicly traded 3D Bioprinting company, commands a market cap of over $500 million with just minuscule […]
While 3D Printing has attracted a great deal of attention from investors because of high growth projections, 3D Bioprinting has attracted investors because of its futuristic appeal. Some companies involved in 3D Bioprinting are raising eyebrows with their lofty ambitions, like private company Modern Meadow which is looking to 3D Print leather, or publicly traded […]